Literature DB >> 31801381

Systemic Adeno-Associated Virus-Mediated Gene Therapy Prevents the Multiorgan Disorders Associated with Aldehyde Dehydrogenase 2 Deficiency and Chronic Ethanol Ingestion.

Yuki Matsumura1, Na Li2, Hanan Alwaseem3, Odelya E Pagovich1, Ronald G Crystal1, Matthew B Greenblatt2,4, Katie M Stiles1.   

Abstract

Aldehyde dehydrogenase type 2 (ALDH2), a key enzyme in ethanol metabolism, processes toxic acetaldehyde to nontoxic acetate. ALDH2 deficiency affects 8% of the world population and 35-45% of East Asians. The ALDH2*2 allele common genetic variant has a glutamic acid-to-lysine substitution at position 487 (E487K) that reduces the oxidizing ability of the enzyme resulting in systemic accumulation of acetaldehyde with ethanol ingestion. With chronic ethanol ingestion, mutations in ALDH2 are associated with a variety of hematological, neurological, and dermatological abnormalities, and an increased risk for esophageal cancer and osteoporosis. Based on our prior studies demonstrating that a one-time administration of an adeno-associated virus (AAV) serotype rh.10 gene transfer vector expressing the human ALDH2 cDNA (AAVrh.10hALDH2) prevents the acute effects of ethanol administration (the "Asian flush syndrome"), we hypothesized that AAVrh.10hALDH2 would also prevent the chronic disorders associated with ALDH2 deficiency and chronic ethanol ingestion. To assess this hypothesis, AAVrh.10hALDH2 (1011 genome copies) was administered intravenously to two models of ALDH2 deficiency, Aldh2 knockout homozygous (Aldh2-/-) and knockin homozygous (Aldh2E487K+/+) mice (n = 10 per group). Four weeks after vector administration, mice were given drinking water with 10-15% ethanol for 12 weeks. Strikingly, compared with nonethanol drinking littermates, AAVrh.10hALDH2 administration prevented chronic ethanol-induced serum acetaldehyde accumulation and elevated liver malondialdehyde levels, loss of body weight, reduced hemoglobin levels, reduced performance in locomotor activity tests, accumulation of esophageal DNA damage and DNA adducts, and development of osteopenia. AAVrh.10hALDH2 should be considered as a preventative therapy for the increased risk of chronic disorders associated with ALDH2 deficiency and chronic alcohol exposure.

Entities:  

Keywords:  AAV gene therapy; ALDH2; esophageal cancer; osteoporosis

Year:  2020        PMID: 31801381      PMCID: PMC7047123          DOI: 10.1089/hum.2019.268

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  104 in total

1.  Trends in gastrectomy and ADH1B and ALDH2 genotypes in Japanese alcoholic men and their gene-gastrectomy, gene-gene and gene-age interactions for risk of alcoholism.

Authors:  Akira Yokoyama; Tetsuji Yokoyama; Toshifumi Matsui; Takeshi Mizukami; Mitsuru Kimura; Sachio Matsushita; Susumu Higuchi; Katsuya Maruyama
Journal:  Alcohol Alcohol       Date:  2013-01-07       Impact factor: 2.826

2.  Reduced bone formation in alcohol-induced osteopenia is associated with elevated p21 expression in bone marrow cells in aldehyde dehydrogenase 2-disrupted mice.

Authors:  Yuki Shimizu; Akinori Sakai; Kunitaka Menuki; Toshiharu Mori; Toyohi Isse; Tsunehiro Oyama; Toshihiro Kawamoto; Toshitaka Nakamura
Journal:  Bone       Date:  2011-01-20       Impact factor: 4.398

Review 3.  Human aldehyde dehydrogenase gene family.

Authors:  A Yoshida; A Rzhetsky; L C Hsu; C Chang
Journal:  Eur J Biochem       Date:  1998-02-01

4.  An optimized method for the measurement of acetaldehyde by high-performance liquid chromatography.

Authors:  Xiangying Guan; Emanuel Rubin; Helen Anni
Journal:  Alcohol Clin Exp Res       Date:  2011-09-06       Impact factor: 3.455

5.  Incident Fragility Fractures Have a Long-Term Negative Impact on Health-Related Quality of Life of Older People: The Canadian Multicentre Osteoporosis Study.

Authors:  Sayem Borhan; Alexandra Papaioannou; Olga Gajic-Veljanoski; Courtney Kennedy; George Ioannidis; Claudie Berger; David Goltzman; Robert Josse; Christopher S Kovacs; David A Hanley; Jerilynn C Prior; Suzanne N Morin; Stephanie M Kaiser; Angela M Cheung; Lehana Thabane; Jonathan Adachi
Journal:  J Bone Miner Res       Date:  2019-02-05       Impact factor: 6.741

6.  N2-ethyldeoxyguanosine as a potential biomarker for assessing effects of alcohol consumption on DNA.

Authors:  Silvia Balbo; Mia Hashibe; Sarolta Gundy; Paul Brennan; Cristina Canova; Lorenzo Simonato; Franco Merletti; Lorenzo Richiardi; Antonio Agudo; Xavier Castellsagué; Ariana Znaor; Renato Talamini; Vladimir Bencko; Ivana Holcátová; Mingyao Wang; Stephen S Hecht; Paolo Boffetta
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-11       Impact factor: 4.254

7.  Pharmacokinetic and pharmacodynamic basis for partial protection against alcoholism in Asians, heterozygous for the variant ALDH2*2 gene allele.

Authors:  Giia-Sheun Peng; Yi-Chyan Chen; Tien-Ping Tsao; Ming-Fang Wang; Shih-Jiun Yin
Journal:  Pharmacogenet Genomics       Date:  2007-10       Impact factor: 2.089

8.  Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease.

Authors:  Margaret Chia-Ying Wey; Elizabeth Fernandez; Paul Anthony Martinez; Patricia Sullivan; David S Goldstein; Randy Strong
Journal:  PLoS One       Date:  2012-02-22       Impact factor: 3.240

Review 9.  The alcohol flushing response: an unrecognized risk factor for esophageal cancer from alcohol consumption.

Authors:  Philip J Brooks; Mary-Anne Enoch; David Goldman; Ting-Kai Li; Akira Yokoyama
Journal:  PLoS Med       Date:  2009-03-24       Impact factor: 11.069

10.  Genotoxic consequences of endogenous aldehydes on mouse haematopoietic stem cell function.

Authors:  Juan I Garaycoechea; Gerry P Crossan; Frederic Langevin; Maria Daly; Mark J Arends; Ketan J Patel
Journal:  Nature       Date:  2012-08-26       Impact factor: 49.962

View more
  2 in total

1.  Primum Non Nocere: Should Gene Therapy Be Used to Prevent Potentially Fatal Disease but Enable Potentially Destructive Behavior?

Authors:  Inmaculada de Melo-Martin; Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2021-04-26       Impact factor: 4.793

Review 2.  Can gene therapy be used to prevent cancer? Gene therapy for aldehyde dehydrogenase 2 deficiency.

Authors:  Rachel A Montel; Carlos Munoz-Zuluaga; Katie M Stiles; Ronald G Crystal
Journal:  Cancer Gene Ther       Date:  2021-11-19       Impact factor: 5.854

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.